High-grade dysplastic nodule (HGDN) is the final premalignant step in the development of hepatocellular carcinoma (HCC) in cirrhotic liver. Dysplastic nodules represent a critical threshold in the hepatocarcinogenesis pathway: regenerative nodule → low-grade dysplastic nodule (LGDN) → high-grade dysplastic nodule → early HCC → advanced HCC. HGDN shows cytological and architectural atypia but lacks definite stromal invasion — this is the most difficult point of differentiation from HCC. On imaging, the 'nodule-in-nodule' pattern is the strongest indicator of HGDN-to-HCC transformation. Size is typically 10-20 mm and the emergence of arterial hypervascularity heralds malignant transformation. In LI-RADS classification, HGDN may fall into LR-3 or LR-4 category; all major criteria must be met for definitive HCC diagnosis.
Age Range
45-75
Peak Age
58
Gender
Male predominant
Prevalence
Uncommon
HGDN arises in the late stage of the chronic liver injury and regeneration cycle. In cirrhotic liver, ongoing hepatocyte damage and telomere shortening lead to genomic instability, causing clonal hepatocyte expansion. The critical vascular change has begun in HGDN: normal portal vein supply decreases and abnormal arterial neovascularization ('unpaired arteries') begins to emerge — but this process is not yet complete. This transitional phase has very important imaging consequences: most HGDNs do not yet show prominent arterial phase enhancement (portal vein loss is not complete) but some show the beginning of mild arterial hypervascularity. On hepatobiliary phase, OATP transporter expression begins to decrease and hypointense appearance emerges when gadoxetic acid is used — this is the earliest functional MR sign differentiating HGDN from regenerative nodule. The 'nodule-in-nodule' pattern indicates that focal HCC transformation has begun within the HGDN: the inner nodule is an early HCC focus that has achieved full arterial neovascularization.
Inner nodule with focal emerging arterial hypervascularity within HGDN — the strongest imaging sign of HCC transformation. The inner nodule represents early HCC that has achieved full arterial neovascularization; the outer nodule (HGDN) is still isovascular/hypovascular.
On T1-weighted imaging, HGDN is typically hyperintense relative to surrounding liver parenchyma. This intrinsic T1 hyperintensity is related to copper accumulation, glycogen storage, or protein content. A T1 hyperintense nodule becoming T1 iso/hypointense over time suggests malignant transformation.
Report Sentence
A _ mm nodule in the cirrhotic liver shows hyperintense signal relative to surrounding parenchyma on T1-weighted sequence.
On T2-weighted imaging, HGDN is isointense or mildly hyperintense relative to surrounding parenchyma. Marked T2 hyperintensity more likely suggests HCC. T2 signal in HGDN is slightly higher than regenerative nodules but lower than HCC — this gradient reflects the hepatocarcinogenesis process.
Report Sentence
The nodule shows isointense/mildly hyperintense signal relative to surrounding parenchyma on T2-weighted sequence.
In the arterial phase, most HGDNs do not show prominent enhancement (isovascular or hypovascular). However, some HGDNs may show the beginning of mild arterial hypervascularity — this is the earliest hemodynamic sign of HCC transformation. In the nodule-in-nodule pattern, the inner component shows prominent arterial enhancement (focal HCC transformation).
Report Sentence
In the arterial phase, the nodule shows iso/hypovascular enhancement relative to surrounding parenchyma; focal emerging arterial enhancement is noted in the inner component.
In the portal venous phase, HGDN is typically isointense or mildly hypointense — but definite washout (marked hypointensity) is not expected. The absence of washout is an important criterion differentiating HGDN from early HCC. In LI-RADS, washout is defined when the lesion becomes hypodense/hypointense compared to surrounding parenchyma in portal venous or delayed phase.
Report Sentence
In the portal venous phase, the nodule shows iso/mildly hypointense signal relative to surrounding parenchyma without definite washout.
When gadoxetic acid is used, HGDN appears hypointense on hepatobiliary phase (15-20 minutes). Gadoxetic acid uptake decreases due to decreased OATP1B1/B3 transporter expression. This is the earliest functional MR sign differentiating HGDN from regenerative nodule — regenerative nodules are isointense or hyperintense on hepatobiliary phase.
Report Sentence
On hepatobiliary phase (gadoxetic acid), the nodule shows markedly hypointense signal relative to surrounding parenchyma — consistent with OATP transporter expression loss, favoring dysplastic nodule/early HCC.
On multiphasic CT, HGDN typically does not show prominent enhancement in the arterial phase — isodense or slightly hypodense relative to surrounding parenchyma. CT sensitivity for detecting HGDN is lower than MRI — especially for small nodules (<15 mm) CT may be insufficient.
Report Sentence
On multiphasic CT, a _ mm nodule in the cirrhotic liver does not demonstrate significant enhancement in the arterial phase.
Criteria
HGDN that does not show enhancement or enhances less than surrounding parenchyma in arterial phase. Portal vein supply is still significantly preserved. Recognized by hypointensity on hepatobiliary phase.
Distinct Features
Most common HGDN type. Falls into LI-RADS LR-3 category. Growth and vascular changes monitored with follow-up MRI.
Criteria
Nodule with an inner component showing focal emerging arterial hypervascularity within HGDN. The inner component represents early HCC.
Distinct Features
Earliest and most reliable imaging evidence of HCC transformation. May be upgraded to LI-RADS LR-4 or LR-5 category. Biopsy is recommended.
Criteria
Dysplastic nodule containing iron (hemosiderin) deposits. Shows marked hypointensity on T2 and T2* sequences. Siderotic nodules are usually low-grade dysplastic or regenerative; however, some HGDNs may also show siderosis.
Distinct Features
T2* hypointensity is diagnostic for siderosis. Loss of siderosis occurs as hepatocarcinogenesis progresses — may indicate malignant transformation.
Distinguishing Feature
In HCC, presence of APHE + washout in portal venous/delayed phase is expected — the lack of developed arterial hypervascularity and absence of washout in HGDN is the key differentiation point. HCC meets LI-RADS 5 criteria while HGDN is typically LR-3.
Distinguishing Feature
Regenerative nodule is isointense/hyperintense on hepatobiliary phase (preserved OATP); HGDN is hypointense. Regenerative nodule is isovascular in arterial phase and size is usually <10 mm.
Distinguishing Feature
LGDN may be iso or mildly hypointense on hepatobiliary phase; HGDN is more markedly hypointense. Nodule-in-nodule pattern is specific to HGDN. Nodules >15 mm favor HGDN.
Distinguishing Feature
Siderotic nodule shows marked hypointensity on T2 and T2* (iron deposition); HGDN is iso or mildly hyperintense on T2. Siderotic nodule is usually isointense on hepatobiliary phase; HGDN is hypointense.
Urgency
surveillanceManagement
surveillanceBiopsy
NeededFollow-up
3-monthHGDN is a harbinger of HCC and requires close follow-up. Follow-up with gadoxetic acid MRI every 3-6 months is recommended. When nodule-in-nodule pattern or development of arterial hypervascularity occurs, biopsy or local treatment (ablation) should be considered. All cirrhotic patients should be enrolled in HCC surveillance program.
High risk of HCC development, requiring close surveillance (MRI at 3-month intervals). May be classified as LR-3 or LR-4 in LI-RADS v2018. Biopsy is controversial due to high risk of sampling error. Development of APHE or washout suggests progression to HCC.